Refractory Tumors Completed Phase 1 / 2 Trials for DB06643 (Denosumab)

Also known as: Refractory Tumor

IndicationStatusPhase
DBCOND0036368 (Refractory Tumors)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03415477Denosumab: A Potential Treatment Option for Aneurysmal Bone CystsTreatment